Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Medicine, Oncology, Urology +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu et al. · The Lancet · 2010 · 3.3K citations

Medicine, Oncology, Pharmacology +16

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Salvatore L. Ruggiero, Thomas B. Dodson, John E Fantasia et al. · Journal of Oral and Maxillofacial Surgery · 2014 · 2.9K citations

Dentistry, Maxillofacial Surgery, Oral Surgery +3

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Medicine, Oncology, Urology +15